Overview
The complexity of new regimens and the need for coordination of care across practice and pharmacy settings has reinforced and expanded the roles of pharmacists. This conference is designed for oncology pharmacists to meet as a larger ecosystem of pharmacists working together to identify and develop solutions for responding clinically and operationally to rapidly evolving evidence reported at the American Society of Clinical Oncology (ASCO) Annual Meeting. The program agenda facilitates bringing pharmacists focused on cancer care from multiple practice settings together to discuss recently presented data; identify resources needed to successfully implement new therapies and make formulary decisions; examine challenges; and brainstorm solutions to meet organizational demands while improving patient outcomes. The core meeting will comprise accredited sessions, with the primary format delivered as panel discussions to enable debate, discussion, and collaborative peer-exchange.
Learning Objectives
Upon completion of this application-based educational conference, pharmacists will be able to:
- Analyze recent clinical updates on novel and emerging pharmacotherapeutic approaches for solid and hematologic malignancies presented at the 2024 American Society of Clinical Oncology Meeting.
- Explain the impact of recent evidence to multiple disease treatment paradigms and challenges to implementation of evolving therapies.
- Apply operational and managed care considerations for the evaluation and integration of changes through formulary decisions, pathways, and resource allocation.
Hot Topics for 2024
Lung cancer; melanoma; breast cancer; gastrointestinal and genitourinary malignancies; hematologic malignancies including multiple myeloma; oncology supportive care; and CAR T-cell and bispecific antibody operational challenges
Program Chairs
Ryan Haumschild, PharmD, MS, MBA
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
To view full profiles, click on the Program Chair tab above.
